Neumora (NASDAQ: NMRA) to sell 146K shares via Merrill Lynch

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. has filed a notice of proposed sale of 146,706 shares of its common stock through Merrill Lynch at 225 Liberty Street, New York, with shares to be sold on or about 08/17/2026 on the NASDAQ. The filing lists an aggregate market value of approximately $220,135.18 for these shares and reports 187,895,912 shares of common stock outstanding as a baseline figure. The securities to be sold were acquired through an exercise of employee stock options for 112,686 shares on 08/17/2026 and through vesting of restricted stock unit awards of 24,375 shares on 02/14/2026 and 9,645 shares on 02/14/2025 under the issuer’s equity compensation plan.

Key Figures

Shares proposed to be sold: 146,706 shares Aggregate market value of shares to be sold: $220,135.18 Shares outstanding: 187,895,912 shares +4 more

7 metrics

Shares proposed to be sold 146,706 shares Common stock to be sold on or about 08/17/2026

Aggregate market value of shares to be sold $220,135.18 Estimated total market value for 146,706 shares of common stock

Shares outstanding 187,895,912 shares Common stock outstanding as referenced in the notice

Shares from option exercise 112,686 shares Acquired via exercise of employee stock options on 08/17/2026

RSUs vested 02/14/2026 24,375 shares Vesting of restricted stock unit awards on 02/14/2026

RSUs vested 02/14/2025 9,645 shares Vesting of restricted stock unit awards on 02/14/2025

Planned sale date 08/17/2026 Approximate date for sale of common stock on NASDAQ

Key Terms

Form 144, broker assisted cashless sale, restricted stock unit awards, equity compensation plan

4 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

broker assisted cashless sale financial

"08/17/2026 | Broker assisted cashless sale"

restricted stock unit awards financial

"Vesting of restricted stock unit awards | Neumora Therapeutics"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

FAQ

What does Neumora Therapeutics (NMRA) report in this Form 144 filing?

Neumora Therapeutics reports a planned sale of 146,706 shares of common stock through Merrill Lynch, with an estimated aggregate market value of $220,135.18. The sale is expected to occur on or about 08/17/2026 on the NASDAQ.

How many Neumora Therapeutics (NMRA) shares are outstanding according to this notice?

The notice states that Neumora Therapeutics has 187,895,912 shares of common stock outstanding. This figure provides context for the planned sale of 146,706 shares, indicating the sale represents a small portion of the total outstanding shares.

What is the source of the Neumora Therapeutics (NMRA) shares to be sold?

The shares come from equity compensation events: 112,686 shares from the exercise of employee stock options on 08/17/2026 and restricted stock unit vestings of 24,375 shares on 02/14/2026 and 9,645 shares on 02/14/2025, granted under the issuer’s equity compensation plan.

What brokerage firm is handling the proposed NMRA share sale under Form 144?

The proposed sale of Neumora Therapeutics common stock will be handled by Merrill Lynch, located at 225 Liberty Street, Floor 37, New York, NY 10281. The shares are expected to be sold on the NASDAQ market.

What is the approximate market value of Neumora Therapeutics (NMRA) shares proposed for sale?

The filing lists an aggregate market value of approximately $220,135.18 for the 146,706 shares of Neumora Therapeutics common stock proposed for sale. This value reflects the estimated total market worth of the shares included in the notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 05:26 PM Accepted by SEC EDGAR 08/17/2026 - 05:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty Street Floor 37 New York NY 10281	146706	220135.18	187895912	08/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	08/17/2026	Exercise of employee stock options	Neumora Therapeutics, Inc.			112686	08/17/2026	Broker assisted cashless sale
Common Stock	02/14/2026	Vesting of restricted stock unit awards	Neumora Therapeutics, Inc.			24375	02/14/2026	Granted as part of issuer equity compensation plan
Common Stock	02/14/2025	Vesting of restricted stock unit awards	Neumora Therapeutics, Inc.			9645	02/14/2025	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)